SCANCELL HLDGS ORD 0.1P (SCLP.L, LSE, LSE:SCLP)

SCLP Share PerformanceMore

52 week high47.000 09/12/13
52 week low23.930 15/11/13
52 week change -6.750 (-17.76%)
4 week volume3,346,690 21/08/14

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Presenting at Upcoming Scientific Conferences

Higher losses at Scancell Holdings

Scancell Holdings, the developer of novel immunotherapies for the treatment of cancer, has announced a loss of 2,222,954 ...

Final Results

Announcement of full year/4th quarter financial results

Scancell Holdings - Synergy of SCIB1 with checkpoint inhibitors

Synergy of SCIB1 with checkpoint inhibitors

Miscellaneous medium priority announcements

Director/PDMR Shareholding

Notification of issuers, persons discharging managerial responsibilities and their connected persons in respect of transactions conducted in their own account in shares of the issuer

Scancell Holdings - SCIB1 Phase 1/2 clinical trial results presented at ASCO and DNA ImmunoBody patent granted in United States

DNA ImmunoBody Patent Granted in United States

Miscellaneous medium priority announcements